Analyzing Solana (NASDAQ:HSDT) and IQVIA (NYSE:IQV)

Solana (NASDAQ:HSDT) and IQVIA (NYSE:IQV) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Solana and IQVIA”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solana	$6.02 million	12.90	-$11.74 million	($490.68)	0.00
IQVIA	$16.31 billion	1.80	$1.36 billion	$7.86	21.97

IQVIA has higher revenue and earnings than Solana. Solana is trading at a lower price-to-earnings ratio than IQVIA, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

18.6% of Solana shares are held by institutional investors. Comparatively, 89.6% of IQVIA shares are held by institutional investors. 17.2% of Solana shares are held by company insiders. Comparatively, 1.7% of IQVIA shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Solana and IQVIA’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Solana	-679.54%	N/A	-25.17%
IQVIA	8.34%	30.50%	6.57%

Analyst Recommendations

This is a summary of recent recommendations for Solana and IQVIA, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solana	1	0	1	0	2.00
IQVIA	0	2	13	2	3.00

Solana presently has a consensus target price of $4.00, suggesting a potential upside of 112.77%. IQVIA has a consensus target price of $229.13, suggesting a potential upside of 32.67%. Given Solana’s higher probable upside, equities analysts plainly believe Solana is more favorable than IQVIA.

Risk and Volatility

Solana has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500. Comparatively, IQVIA has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Summary

IQVIA beats Solana on 12 of the 15 factors compared between the two stocks.

About Solana

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-implantable technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a non-surgical medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company was incorporated in 2014 and is headquartered in Newtown, Pennsylvania.

About IQVIA

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients’ outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.